CXCL17 and COVID-19: In contrast, no differences in serum CXCL17 levels at admission were observed between survivor- and deceased-COVID-19 patients (Figure 3C), and this chemokine showed no correlation with the lung damage score of patients with PTB (Supplementary Figure 3).